Ovarian Reserve Test - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510242037

Publication Date:

October 28, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

Declining follicular pool and oocyte quality specially in the mid to late thirties.

This age-related decline of follicles in the human ovary is supposed to be more than double when numbers fall below a critical figure of 25,000 at ~37.5 years of age. According to World Health Organization (WHO), the number of women age 60 and over will increase from about 336 million in 2000 to just over 1 billion in 2050.

Moreover, safety and efficacy associated with ovarian reserve tests is likely to increase the demand in the near future. Manufacturers are also developing home testing kits for ovarian reserve test also provides easy accessibility and availability for checkups which is likely to rise the demand.

Ovarian surgeries also play an important role in driving the market, since removal of cysts can also result in diminished ovarian follicle in women. Thus, all these factors are likely to increase the market growth in the forecast period.
The global market for Ovarian Reserve Test was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Ovarian Reserve Test was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Ovarian Reserve Test was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Ovarian Reserve Test was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Ovarian Reserve Test include Beckman Coulter, Fujirebio, F. Hoffmann-La Roche Ltd, Everlywell, LabCorp, VIDAS, Modern Fertility, Future Family and LetsGetChecked, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ovarian Reserve Test, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Ovarian Reserve Test by region & country, by Type, and by Application.
The Ovarian Reserve Test market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ovarian Reserve Test.
麻豆原创 Segmentation
By Company
Beckman Coulter
Fujirebio
F. Hoffmann-La Roche Ltd
Everlywell
LabCorp
VIDAS
Modern Fertility
Future Family
LetsGetChecked
EggQ
Segment by Type:
Follicle Stimulating Hormone (FSH) Testing
Anti-Mullerian hormone (AMH) Testing
Antral Follicle Count Testing
Basal Follicle Stimulating Hormone Testing
Segment by Application
Hospitals
IVF Centers
Diagnostic Centres
Ambulatory Surgical Centres
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Ovarian Reserve Test manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Ovarian Reserve Test in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Ovarian Reserve Test in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Ovarian Reserve Test Product Introduction
1.2 Global Ovarian Reserve Test 麻豆原创 Size Forecast
1.3 Ovarian Reserve Test 麻豆原创 Trends & Drivers
1.3.1 Ovarian Reserve Test Industry Trends
1.3.2 Ovarian Reserve Test 麻豆原创 Drivers & Opportunity
1.3.3 Ovarian Reserve Test 麻豆原创 Challenges
1.3.4 Ovarian Reserve Test 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Ovarian Reserve Test Players Revenue Ranking (2023)
2.2 Global Ovarian Reserve Test Revenue by Company (2019-2024)
2.3 Key Companies Ovarian Reserve Test Manufacturing Base Distribution and Headquarters
2.4 Key Companies Ovarian Reserve Test Product Offered
2.5 Key Companies Time to Begin Mass Production of Ovarian Reserve Test
2.6 Ovarian Reserve Test 麻豆原创 Competitive Analysis
2.6.1 Ovarian Reserve Test 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Ovarian Reserve Test Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ovarian Reserve Test as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Follicle Stimulating Hormone (FSH) Testing
3.1.2 Anti-Mullerian hormone (AMH) Testing
3.1.3 Antral Follicle Count Testing
3.1.4 Basal Follicle Stimulating Hormone Testing
3.2 Global Ovarian Reserve Test Sales Value by Type
3.2.1 Global Ovarian Reserve Test Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Ovarian Reserve Test Sales Value, by Type (2019-2030)
3.2.3 Global Ovarian Reserve Test Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 IVF Centers
4.1.3 Diagnostic Centres
4.1.4 Ambulatory Surgical Centres
4.1.5 Others
4.2 Global Ovarian Reserve Test Sales Value by Application
4.2.1 Global Ovarian Reserve Test Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Ovarian Reserve Test Sales Value, by Application (2019-2030)
4.2.3 Global Ovarian Reserve Test Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Ovarian Reserve Test Sales Value by Region
5.1.1 Global Ovarian Reserve Test Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Ovarian Reserve Test Sales Value by Region (2019-2024)
5.1.3 Global Ovarian Reserve Test Sales Value by Region (2025-2030)
5.1.4 Global Ovarian Reserve Test Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Ovarian Reserve Test Sales Value, 2019-2030
5.2.2 North America Ovarian Reserve Test Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Ovarian Reserve Test Sales Value, 2019-2030
5.3.2 Europe Ovarian Reserve Test Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Ovarian Reserve Test Sales Value, 2019-2030
5.4.2 Asia Pacific Ovarian Reserve Test Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Ovarian Reserve Test Sales Value, 2019-2030
5.5.2 South America Ovarian Reserve Test Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Ovarian Reserve Test Sales Value, 2019-2030
5.6.2 Middle East & Africa Ovarian Reserve Test Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Ovarian Reserve Test Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Ovarian Reserve Test Sales Value
6.3 United States
6.3.1 United States Ovarian Reserve Test Sales Value, 2019-2030
6.3.2 United States Ovarian Reserve Test Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Ovarian Reserve Test Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Ovarian Reserve Test Sales Value, 2019-2030
6.4.2 Europe Ovarian Reserve Test Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Ovarian Reserve Test Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Ovarian Reserve Test Sales Value, 2019-2030
6.5.2 China Ovarian Reserve Test Sales Value by Type (%), 2023 VS 2030
6.5.3 China Ovarian Reserve Test Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Ovarian Reserve Test Sales Value, 2019-2030
6.6.2 Japan Ovarian Reserve Test Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Ovarian Reserve Test Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Ovarian Reserve Test Sales Value, 2019-2030
6.7.2 South Korea Ovarian Reserve Test Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Ovarian Reserve Test Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Ovarian Reserve Test Sales Value, 2019-2030
6.8.2 Southeast Asia Ovarian Reserve Test Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Ovarian Reserve Test Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Ovarian Reserve Test Sales Value, 2019-2030
6.9.2 India Ovarian Reserve Test Sales Value by Type (%), 2023 VS 2030
6.9.3 India Ovarian Reserve Test Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Beckman Coulter
7.1.1 Beckman Coulter Profile
7.1.2 Beckman Coulter Main Business
7.1.3 Beckman Coulter Ovarian Reserve Test Products, Services and Solutions
7.1.4 Beckman Coulter Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.1.5 Beckman Coulter Recent Developments
7.2 Fujirebio
7.2.1 Fujirebio Profile
7.2.2 Fujirebio Main Business
7.2.3 Fujirebio Ovarian Reserve Test Products, Services and Solutions
7.2.4 Fujirebio Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.2.5 Fujirebio Recent Developments
7.3 F. Hoffmann-La Roche Ltd
7.3.1 F. Hoffmann-La Roche Ltd Profile
7.3.2 F. Hoffmann-La Roche Ltd Main Business
7.3.3 F. Hoffmann-La Roche Ltd Ovarian Reserve Test Products, Services and Solutions
7.3.4 F. Hoffmann-La Roche Ltd Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.3.5 Everlywell Recent Developments
7.4 Everlywell
7.4.1 Everlywell Profile
7.4.2 Everlywell Main Business
7.4.3 Everlywell Ovarian Reserve Test Products, Services and Solutions
7.4.4 Everlywell Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.4.5 Everlywell Recent Developments
7.5 LabCorp
7.5.1 LabCorp Profile
7.5.2 LabCorp Main Business
7.5.3 LabCorp Ovarian Reserve Test Products, Services and Solutions
7.5.4 LabCorp Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.5.5 LabCorp Recent Developments
7.6 VIDAS
7.6.1 VIDAS Profile
7.6.2 VIDAS Main Business
7.6.3 VIDAS Ovarian Reserve Test Products, Services and Solutions
7.6.4 VIDAS Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.6.5 VIDAS Recent Developments
7.7 Modern Fertility
7.7.1 Modern Fertility Profile
7.7.2 Modern Fertility Main Business
7.7.3 Modern Fertility Ovarian Reserve Test Products, Services and Solutions
7.7.4 Modern Fertility Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.7.5 Modern Fertility Recent Developments
7.8 Future Family
7.8.1 Future Family Profile
7.8.2 Future Family Main Business
7.8.3 Future Family Ovarian Reserve Test Products, Services and Solutions
7.8.4 Future Family Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.8.5 Future Family Recent Developments
7.9 LetsGetChecked
7.9.1 LetsGetChecked Profile
7.9.2 LetsGetChecked Main Business
7.9.3 LetsGetChecked Ovarian Reserve Test Products, Services and Solutions
7.9.4 LetsGetChecked Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.9.5 LetsGetChecked Recent Developments
7.10 EggQ
7.10.1 EggQ Profile
7.10.2 EggQ Main Business
7.10.3 EggQ Ovarian Reserve Test Products, Services and Solutions
7.10.4 EggQ Ovarian Reserve Test Revenue (US$ Million) & (2019-2024)
7.10.5 EggQ Recent Developments
8 Industry Chain Analysis
8.1 Ovarian Reserve Test Industrial Chain
8.2 Ovarian Reserve Test Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Ovarian Reserve Test Sales Model
8.5.2 Sales Channel
8.5.3 Ovarian Reserve Test Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Beckman Coulter
Fujirebio
F. Hoffmann-La Roche Ltd
Everlywell
LabCorp
VIDAS
Modern Fertility
Future Family
LetsGetChecked
EggQ

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.